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ABSTRACT

FACTORS EFFECTING CALCIFICATION
OF BIOPROSTHETIC HEART VALVES
by
Sumei Yu

Calcification is the most frequent cause of clinical dysfunction of
glutaraldehyde treated bioprosthetic heart valves. In this study, we compared
calcification of bioprostheses of the No-ReactTM and the conventional
glutaraldehyde treated pericardium by both in-vivo and in-vitro methods, and to
further delineate the role of the host's inflammatory response in implant
degeneration.
In the in-vitro study, the two types of pericardial samples were placed in
individual polystyrene tubes containing physiological concentrations of calcium
and phosphate and incubated for 21 days at 37°C. In the in-vivo study, the two
types of pericardial samples were implanted subcutaneously in rats and
subsequently retrieved at 15, 21, and 35 days postimplantation. Calcium analyses
were performed on each specimen.
Experimental results showed that a significantly reduced in vitro
calcification of No-ReactTM treated pericardium compared to conventional
glutaraldehyde pretreated tissue (mean calcium content, 1.3 ± 0.2 g/mg of NoReactTM treated tissue versus 5.8 ± 0.7 µg/mg of glutaraldehyde pretreated tissue)
(p < 0.001). In-vivo test showed progressive calcification of glutaraldehyde treated
pericardium over 5-week period (mean tissue calcium content increasing from 49.6
± 9.6 µg/mg after 2-week to 134.3 ± 9.1 big/mg at 5 weeks postimplantation),

while No-ReactTM treated pericardial tissue calcified significantly less (p < 0.05) in
20-30 µg/mg level at each corresponding interval.
All these lead to the conclusion that the calcification of conventional
glutaraldehyde treated pericardium is more severe than No-ReactTM treated
pericardium both in vivo and in vitro tests.

FACTORS EFFECTING
CALCIFICATION OF BIOPROSTHETIC HEART VALVES

by
Sumei Yu

A Thesis
Submitted to the Faculty of
New Jersey Institute of Technology
in Partial Fulfillment of the Requirements for the Degree of
Master of Science in Applied Chemistry
Department of Chemical Engineering,
Chemistry, and Environmental Science
October 1995

APPROVAL PAGE

FACTORS EFFECTING
CALCIFICATION OF BIOPROSTHETIC HEART VALVES

Sumei Yu

Dr. David Kristol, Thesis Advisor
Professor of Chemistry and Graduate Advisor of Biomedical Engineering
New Jersey Institute of Technology

Dr. Shlomo Gabbay
ember
Associate Professor
Surgery (Cardiothoracic)
University o Medicine and Dentistry of New Jersey

Dr. Carol Venanzi, Committee Member
Professor of Chemical Engineering, Chemistry, and Environmental Science
New Jersey Institute of Technology

Date

7 Date

Date

BIOGRAPHICAL SKETCH

Author:

Sumei Yu

Degree:

Master of Science in Applied Chemistry
October 1995

Date:

Undergraduate and Graduate Education:
•

Master of Science in Applied Chemistry
New Jersey Institute of Technology,
Newark , New Jersey, 1995

•

Bachelor of Science in Chemical Engineering
East China University of Chemical Technology,
Shanghai, P. R. China, 1988

Major:

Applied Chemistry

This thesis is dedicated to my husband

v

ACKNOWLEDGMENT

I would like to take this opportunity to acknowledge and give my gratitude
for the help and guidance given to me by Dr. Shlomo Gabbay, Dr. David Kristol
and Dr. Carol Venanzi, without which this work would not have been possible.
A special thank goes to my colleagues at UMDNJ. Their knowledge,
wisdom, time, and effort have made an invaluable contributions to the conduct of
the research as the completion of this thesis. More importantly their friendship has
made my time at UMDNJ an enjoyable experience. Mr. Xu, Qi Lu and Dr. Amir
Abolhoda, I am fortunate to have them as laboratory co-workers.
Thanks to Mr. Francis W. Kemp and Mr. Shenggao Han for the enormous
help and support given to me in the performance of analytic chemistry and atomic
absorption testing. They helped not only performing the testing but also making
them available to me with its special laboratory equipment. Special thanks to Dr.
John Bogaden to contributing time and his laboratory to complete this work.

vi

TABLE OF CONTENTS

Chapter

Page

1 INTRODUCTION

1

2 METHOD OF STATIC IN-VITRO TESTS

6

2.1 Preparation of Instruments and Solutions

6

2.2 Procedure

7

3 METHOD OF PRONASE DIGESTION TESTS

10

3.1 Materials

10

3.2 Procedure

11

3.3 Calculation

12

4 METHOD OF SUBCUTANEOUS IMPLANTS AND
EXPLANTS IN RATS

13

4.1 Preparation

13

4.2 Procedure

14

4.2.1 Implantation procedures

14

4.2.2 Explantation procedures

14

5 CALCIUM DETERMINATION BY ATOMIC ABSORPTION
SPECTROPHOTOMETER

16

5.1 Apparatus and Reagents

16

5.2 Solution Sample Acquisition and Preparation

17

5.3 Tissue Sample Acquisition and Preparation

17

5.4 Standard Solution Preparation

19

5.5 Analytic Procedures

70

5.6 Calculation

21

5.6.1 Calcium Content in Solution Samples
5.6.2 Calcium Content in Tissue Samples
6 RESULTS

21
23

vii

TABLE OF CONTENTS
(Continued)

Chapter

Page

6.1 In-Vitro Calcification

23

6.1.1 Solution Sample Analysis Result In-Vitro Studies

23

6.1.2 Tissue Sample Analysis In-Vitro Studies

23

6.1.3 Macroscopic Observation

26

6.2 Pronase Digestion Test

26

6.3 In-Vivo Test---Subcutaneously Implants in Rats

26

7 DISCUSSION

28

8 SUMMARY

41

APPENDIX A

42

APPENDIX B

52

REFERENCES

59

viii

LIST OF TABLES

Page

Table
6.1 In-Vitro Calcification Data: Calcium Content in the Incubation Solutions

24

6.2 In-Vitro Calcification Data: 21 Days Incubation Results(Tissue Samples)

43

6.3 In-Vitro Calcification Data: 56 Days Incubation Results(Tissue Samples)

44

6.4 In-Vitro Calcification Data: Calcium Spots on the Pericardial Samples

45

6.5 Pronase Digestion Data: No-ReactTM Treated Samples

46

6.6 Pronase Digestion Data: Glutaraldehyde Treated Samples

47

6.7 Pronase Digestion Data: Fresh Pericardial Samples

48

6.8 In-Vivo Calcification Data: Comparison of Calcium Content between
No-React' and Glutaraldehyde Treated Tissue Samples (15 days)

49

6.9 In-Vivo Calcification Data: Comparison of Calcium Content between
No-ReactTM and Glutaraldehyde Treated Tissue Samples (21 days)

50

6.10 In-Vivo Calcification Data: Comparison of Calcium Content between
No-ReactTM and Glutaraldehyde Treated Tissue Samples (35 days)

51

ix

LIST OF FIGURES

Figure

Page

6.1 21 Days In-Vitro Tests (Pericardial Samples)

53

6.2 Comparison of Calcification Rate between the No-React
and Glutaraldehyde Treated Tissue Samples (56 days)

54

6.3 Calcium Spots on Pericardial Sample(In-VitroTests)

55

6.4 Comparison of Calcification Rate In-Vivo Tests (15 days)

56

6.5 Comparison of Calcification Rate In-Vivo Tests (21 days)

57

6.6 Comparison of Calcification Rate In-Vivo Tests (35 days)

58

CHAPTER 1

INTRODUCTION

Heart valve bioprostheses were introduced about 35 years ago to cope with the
major disadvantage of mechanical valves. After 35 years of valve replacement, it
is fair to state that the operation can be considered as a cure for the short term,
especially if large-size valves can be used, but only palliative for the long-term,
and for a certain group of patients this operation can not be considered curative in
any stage after the operation (children , women in child-bearing age, etc.). Valve
replacement with a mechanical valve can never be considered curative because of
the continuous need for anticoagulation as well as the continuous risk (although
small) of sudden death, while a biological valve can give excellent quality of life.
There is also ample evidence today that anti-platelets may be sufficient in cases of
atrial fibrillation, or when patient had an episode of thromboembolism after valve
replacement with bioprostheses. The quality of life with well-functioning biologic
prosthesis is reported to be better than that with a mechanical valve.
Formaldehyde and particularly glutaraldehyde, are commonly used to
control the physical and biological properties of a variety of collagen-based
biomaterials such as heart valve and blood vessel prostheses, implantable collagen
preparations and collagen dressings.
The first porcine xenograft valves were treated with formaldehyde,
unfortunately they failed relatively early (1). Although formalin solution is an
excellent sterilizing agent with profound tanning effects, the alternation of
collagen by formalin is thought to be caused by polycondensation of protein chains
(2), and the polymerization is reversed after implantation, thus the deterioration is
accelerated by the original formalin effect. Formalin preservation of heterograft
aortic valves has proved unsatisfactory in both experimental and clinical trials (1).
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Malfunctioning valves examined after implantation are identical in both series,
showing a diffuse process of deterioration. Changes of formalin concentration and
storage conditions do not influence the findings significantly. This nonviable tissue
is rarely repopulated by host tissue over the period of time studied, making the
likelihood of satisfactory extended function improbable. So the use of
formaldehyde has been abandoned fairly quickly (1).
The glutaraldehyde tanning method was proposed to solve the problem of
availability with the allograft and tissue failure with the formalin treated
xenograft. The use of weak glutaraldehyde solution did in fact provide more
permanent fixation of porcine valve collagen, increasing tissue durability and
enabling commercial marketing of this type of valves (3).
Bioprostheses fabricated from glutaraldehyde-preserved porcine aortic
valve or bovine pericardium are widely used to replace diseased human cardiac
valves. Glutaraldehyde is used to control physical and biological properties of
collagen structure by means of intermolecular and/or intermolecular cross-linking
of collagen molecules. Solubility, antigenicity, and biodegradation of naturally
occuring or reconstituted collagenous matrices are effectively reduced by
glutaraldehyde treatment. Glutaraldehyde treatment decreased inflammatory
reaction by reducing antigenicity and destruction of the implant. Contrary to the
formaldehyde, the cross-linking is more stable (3).
As the glutaraldehyde preserved porcine xenografts are widely used,
durability remains the primary concern. Spontaneous, sterile deterioration of the
glutaraldehyde preserved porcine xenograft appears to occur as a result of
calcification, which may either stiffen and immobilize the valve leaflets or deform
and stress them to the point of rupture. Calcification can be readily documented
grossly by radiography and by histologic section, accurate measurement of the
calcium content can be performed by atomic absorption spectrophotograpy.
Calcification is proposed to occur by two basic mechanisms. One is the deposition
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of crystalline material in denuded, disrupted exposed, or thrombosed regions of the
leaflet, and the second is the presence of an innate, diffuse stippling of crystalline
substances in the collagen bundles of the porcine leaflet itself (4, 5, 6, 7).
Several factors are proposed to be related to this process:
1. Calcium metabolism of the individual patient and host versus graft reaction,
2. Turbulence of blood flow through the valve,
3. The degree of valve tissue fixation,
4. Valve leaflet flexibility , and
5. The presence of thrombus on the valve leaflets.
Another possible mechanisms suggested that it might be an immunological
response. In addition to these the calcification may also occur in valves implanted
in patients with no apparent risk factors.
It was stated that the 5 year valve failure rate from spontaneous, sterile
degeneration of valves manufactured from 1970 to 1975 is 7.1% (6/65) of those
implanted (8). The number of patients is too small to predict a 10 year failure rate
for valves implanted in the early 1970s, but there is some evidence to suggest that
this failure rate is less than 20%. Nevertheless, commercial glutaraldehyde
preserved porcine tissue valves have been shown to be functional in the twelfth
year of implantation (3, 9)(reports of 20 years are available). At present , about
20 ~ 25% of adult patients and 50% of children patients have to be reoperated in
less than 10 years. The undefined durability is the major drawback of
bioprostheses. Clinical regurgitation, stenosis, or both, are frequently caused by
calcification , with or without cuspal tearing, necessitating reoperation with valve
removal or causing death of approximately 25% of patients with porcine
bioprostheses within 10 years postoperatively.
While degeneration of bioprostheses is often a slowly progressing
phenomenon that can allow for planned reoperation. The prosthetic valves made of
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glutaraldehyde fixed porcine aortic valve and bovine pericardium have been used
in more than 500,000 patients.
However, the main problems associated with the failure of bioprosthetic
valves are calcification which can lead to stenosis or insufficiency. Calcification
in children remains a serious problem. Bioprosthetic valves are practically
contraindicated in children and mechanical valves are contraindicated in patients
who can not receive anticoagulants. Socioeconomic factors constitute a relative
contraindication to the use of mechanical valves, a high incidence of
thromboembolic complications in patients with mechanical cardiac valvular
prostheses during the late 1960s and early 1970s generated interest in valves made
of biologic materials, e.g., fascia lata, duramater, porcine aortic valves, and bovine
pericardium.
Glutaraldehyde treatment has been thought as main "villain" in
calcification. Extensive clinical and pathological studies have demonstrated that
these tissue valves treated with glutaraldehyde undergo degeneration and
calcification, especially in children and adolescents (10, 11, 12).
Schoen et al. (13), reported that subcutaneously implanted porcine aortic
valve showed calcification from 2 — 56 days, after which, up to 126 days, there is
no further increase.

And the subcutaneously implanted porcine aortic

bioprosthesis develops collagen calcification after 21 days if pretreated with
glutaraldehyde, with fresh valve cusps implants demonstrated only a minimal
necrosis without calcification during same period of implantation (13).
Both porcine aortic valve and pericardium are rich in type I collagen, and it
has been suggested that the inflammatory response is due to chemotactic potential
of collagen peptides generated from the collagenase digestion.
Schoen et al. have concluded that the presence of glutaraldehyde is a
prerequisite for calcium deposition (13).
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In this study, we compared calcification of bioprostheses by in vitro and
vivo methods to study the effect of conventional glutaraldehyde treated and the
No-ReactTM anticalcification treatment on calcification, and to correlate
inflammation and calcification.
The experiment consists of the following tests:
I. Static In-Vitro calcification tests.
2. Pronase digestion tests.
3. Rats subcutaneous implantation of pericardial strips.
This study is part of a larger investigation performed at the UMDNJ-NJMS
Cardiothoracic Research Laboratory, to try to elucidate the different factors
responsible for the degeneration and calcification of xenograft tissues.

CHAPTER 2

METHOD OF STATIC IN-VITRO CALCIFICATION TESTS

In-vitro systems are simpler, cheaper and more easily controlled than in-vivo
systems. Static in-vitro test systems can be used to study small samples of
material in large numbers relatively quickly, and has a useful role to play in the
economic screening of new materials or modifications of existing materials prior
to in-vivo testing . It may also aid the definition of the mechanism of calcification
and hence the development of solutions to the problem.
In the test, solution composition was specifically chosen to be as simple and
as close to physicologic concentrations as possible, and still achieve calcification,
allowing the parameters involved in the process to be kept at a minimum.
In this test, we compared the calcification of conventional glutaraldehyde
treated and No-ReactTM treated pericardium.

2.1 Preparation of Instruments and Solutions
1. Vials
clean , sterile, screw-top polystyrene sample vials.
2. Tissue samples
a. pericardium treated with conventional glutaraldehyde treatment,
No-ReactTM
b.
treated pericardium.
3. Solution
a. solution A:
15782 mg NaCl, 738.7mg CaCl2 2H20, 326 mgKH2PO4, 20.9mg MOPS were
weighed. Solution were made in 2 liters millipore water. Solution containing 135
mM NaCl, 2.88 mM CaCl2 2H20, 1.2 mM KH2 PO4, 0.05 mM MOPS. Certain
amount of 0.25 M NaOH was added to adjust the pH to 7.40, while the solution
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was stirred. Then, under aseptic condition, the solution was forced through a filter
(0.2 µm) as a method sterilization.
b. solution B (saline solution):
0.9 % NaCl, pH = 7.40, autoclave to sterilize the solution

2.2 Procedure
1. Basin, scissors, clasps , towels etc were autoclaved.
2. Under laminar flow hood, the No-ReactTM treated pericardium was cut into 3 cm
x 1 cm, washed with solution B in the sterile basin, stirred gently for 30 min.
Same process for the glutaraldehyde treated pericardium samples in a different
basin was performed.
3. Each sample was placed in individual vial with 20 ml solution A,
4. The experiments were divided by following groups:
Group 1----temperature of 37°C, 21 days, the solution was changed every week.
(5 vials of each type of tissue)
labelled as: G1-1 G1-2 G1-3 G1-4 G1-5
N1-1 Ni-2 N1-3 N1-4 N1-5
where, G, represents the conventional glutaraldehyde treated samples,
N, represents the No-React'TM treated samples,

Group 2----temperature of 37°C, 21days, the solution was not changed at any time.
(5 vials of each type of tissue).
labelled as: G2-1 G2-2 G2-3 G2-4 G2-5
(conventional glutaraldehyde treatment)
N2-1 N2-2 N2-3 N2-4 N2-5
(No-ReactTM treated tis ues)

Group 3----temperature of 25°C, 56 days, the solution was changed every week.
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(5 vials of each type of tissue)
labelled as: G3-1 G3-2 G3-3 G3-4 G3-5
(conventional glutaraldehyde treatment)
N3-1 N3-2 N3-3 N3-4 N3-5
(No-ReachTM treated tissues)

Group 4----temperature of 37°C, 56 days, the solution was changed every week.
(5 vials of each type of tissue)
labelled as: G4-1 G4-2 G4-3 G4-4 G4-5
(conventional glutaraldehyde treatment)
N4-1 N4-2 N4-3 N4-4 N4-5
(No-ReactTM treated tis ues)

Group 5---- control group. Use solution B instead of solution A as a control
solution for both glutaraldehyde and No-ReachTM treated pericardium samples.
Temperature of 37°C, 21 days, the solution was not changed at any time.
(5 vials of each type of tissue)
labelled as : SG1 SG2 SG3 SG4 SG5
(conventional glutaraldehyde treatment)
SN1 SN2 SN3 SN4 SN5
(No-ReactTM treated tis ues)

5. For group 1, the previous solution was replaced by a fresh solution every week,
monitored every week. After 21 days the tissues were removed and washed with
solution B, dried and digested with nitric acid and perchloric acid (with ratio of
3:1) , then analyzed for calcium content.
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6. For group 2, after the period of 21 days, the concentration of calcium in the
solution was monitored by atomic absorption spectroscopy. The tissue was
removed, washed with solution B, and then dried, digested with nitric acid and
perchloric acid (with ratio of 3:1), then analyzed for calcium content by atomic
absorption spectroscopy.

7. For group 3 and 4, the old solution was replaced by a fresh solution, and
monitored every week. After 56 days , the tissue was removed from the vials,
washed with solution B, dried and digested with nitric acid and perchloric acid
(with ratio of 3:1), then analyzed for calcium content by atomic absorption
spectroscopy.

8. For the control group, the tissue was removed from the vials after 21 days,
dried and digested, then analyzed for calcium content by atomic absorption
spectroscopy.

CHAPTER 3

METHOD FOR PRONASE DIGESTION TESTS

Subcutaneously implanted porcine aortic bioprostheses develop collagen
calcification after 21 days if pretreated with glutaraldehyde, while fresh valve cusp
implants demonstrate only a minimal necrosis without calcification during same
period of implantation. Both porcine aortic valve and pericardium are rich in type
I collagen , and it has been suggested that the inflammatory response is due to
chemotactic potential of collagen peptides generated from the collagen digestion.
Three groups of differently treated pericardiums were digested with pronase
in this study to compare the weight lost by each group of pericardium during the
pronase digestion process and correlate that information with the inflammation
and calcification.

3.1 Materials
1. Chemicals
a. Pronase P5147 5.5 units/mg solid, Type XIV Bacterial
from Streptomyces griseus. Lot# 34H0331ordered from SIGMA Company
b. Glycine G6388

Lot# 84H05445 ordered from SIGMA Company

c. HEPES H9136 Lot# 64H5725 ordered from SIGMA Company
d. CaC12·2H20

2. Pericardial samples
a. Fresh pericardium Lot# 941026
b. No-ReactTM treated pericardium Lot# 950102-11
c. Glutaraldehyde treated pericardium Lot# 950103
3. Sterile single-use polystyrene tubes
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3.2 Procedure
1.Solution preparation
75 mg CaC12.2H20, 1.125 g glycine, 1g HEPES were weighed, mixed in 150 ml
millipore water. Certain amount of 0.25 M NaOH was added to adjust the pH to
7.40, then 75 mg protease was added.

2. Pericardial samples preparation
The samples (n = 10 for each fresh pericardium, No-react'" pericardium and
conventional glutaraldegyde-treated pericardium) were cut into 1cm x 3cm shape.
These samples were labelled and blotted with clean, dry towel, then each piece was
cut into two pieces, one was about 1cm x 1cm, another was about 1cm x 2 cm. Each
piece was weighed simultaneously. The weights were recored as "initial wet weight
of the large piece" and "initial wet weight of the small piece".

3. Dry sample
The small pieces were put into clean polystyrene plates (the plates were labelled
from Fl to F10 for fresh pericardial samples, from N1 to N10 for No-ReactTM
treated pericardial samples, from G1 to G10 for conventional glutaraldegyde
treated pericardial samples), these plates (without cover) were put into 37°C oven
and dried for at least 2 hours or until the weight was constant. Then the samples
were weighed and recorded as "dry weight of the small piece".

4. Digestion
The large pieces were put into polystyrene tubes. 3m1 solution made in procedure
1 was added into each tube. Tubes were covered, labelled and put in 50 °C
shaking bath for 22 hours.
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5. Weight recording
After 22 hours, the tubes were removed out of the shaking bath. The samples were
taken out, blotted with clean towel to remove the free water, weighed and recorded
as "wet weight of large piece after digestion". These samples were put in the
clean polystyrene plates and dried in 37 °C oven for at least 2 hours or until
constant weight. These weight were record as "dry weight of large piece".

3.3 Calculation
1. The "dry weight of small pieces" divided by "initial wet weight of small pieces"
is the ratio of blotted/dry weight of the small samples, and this will be used to
calculate the initial dry weight of the large samples based on their initial blotted
weight. These steps are necessary because:
a. The samples can not be dried before the protease digestion,
b. During protease digestion, the hydrophilic ability of the tissue will change,
thereby increasing considerably the blotted weight of the sample, leading to
erroneous results.

2. "Initial wet weight of large piece" times "ratio of blotted/dry weight "gave the
"initial dry weight of large piece", which was the weight of large piece before
digestion.

3. The proportion of the final dry weight/initial dry large weight for the large
pieces represented the weight left after digestion. And (1 - proportion ) x 100%
gave the weight loss during the incubation process due to the enzymatic
degradation induced by the non-specific protease agent. The results were
expressed for each experimental condition as mean ± SEM weight lost (% of
initial weight).

CHAPTER 4

METHOD OF SUBCUTANEOUS IMPLANTS AND EXPLANTS IN RATS

This in-vivo study was performed to compare the calcification of conventional
glutaraldehyde treated pericardium and No-ReactTm treated pericardium.
Samples of the two types of pericardiums were implanted in the rats under
different side of the skin in abdominal wall. After few weeks, the samples were
retrieved and analyzed. The pericardial samples were treated with the Biocor
processes.

4.1 Preparation
1. Rats
20 male sprague-dawley rats of 4 weeks old, 60 ~ 80 grams
2. Pericardial samples
20 conventional glutaraldehyde treated samples, with size of cm x 2cm,
Lot # 950202,
20 No-React" treated samples , with size of 1cm x 2cm, Lot # 950102-II
3. Anesthesia reagents
The animals were injected intrabdominally with a cocktail of a total of 1-3 ml of
Ketamine (20 mg/ml ), Xylazine (2.5 mg/ml ) and Pentobarbital.
4. Other
5-0 coated vicryl suture,
1cc syringes ,
Scissors, clamp, basin, clean towel etc.
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4.2 Procedure
4.2.1 Implantation Procedures
1. The surgical tools have been autoclaved.
2. Pericardial samples were washed in separate saline bath.
3. The rats were anesthesized with 1 ml ketamine cocktail, with the rats head
down.
4. Once in deep sleep, the rats were prepared and wrapped.
5. Anterior abdominal wall was prepared sterilly with betadine solution and draped
with sterile towels. Two subcutaneous pockets were created on anterior abdominal
wall for accommodation of 1 cm x 2cm pre-cut segments of conventional
glutaraldehyde treated and No-ReactTM treated pericardium. The pericardium strips
were implanted subcutaneously in the abdominal wall, the No-ReactTM treated
tissue was implanted in the right side, while the conventional glutaraldehyde
treated pericardium strip was implanted in the left side.
6. The skin was closed with labelled 5-0 vicryl sutures.
7. The rats were fed Lab Rodent Diet (Purina Meals Inc.) and received humane
care in compliance with the "Principles of Laboratory Animal Care" formulated by
the National Society For Medical Research and the "Guide For the Care and Use
of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources
and published by National Institutes of Wealth (NIH Publication No. 86-23,
revised 1985).

4.2.2 Explantation Procedures
1. The rats were sacrificed by intraperitoneal overdose injection (300 mg /kg ) of
pentobarbital after 2, 3, 5 weeks, respectively.
2. The pericardial samples were retrieved from abdominal wall,

labeled

appropriately for both conventional glutaraldehyde treated and No-ReactTM treated
pericardium as G(i) or N(i), where i stands for each rat.
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3. Small strips were cut from each sample, placed in 10% buffer formalin for
histological examination .
4. Each sample was washed with sterile 0.9 % NaCI before analysis.

CHAPTER 5

CALCIUM DETERMINATION BY ATOMIC ABSORPTION
SPECTROPHOTOMETER
Both in-vitro and in-vivo test, the calcium content of samples were measured by
atomic absorption spectrophotometry. Flame atomic absorption spectrophptometer
was used to perform the analysis. The wavelength used to measure the calcium
was 428 nm. National Institutes of standards and Technology bovine Liver (SRM
1577a, Gaithersburg, MD) was used as a quality control sample for all calcium
content analyses.

5.1 Apparatus and Reagents
1. Apparatus
a. Flame Atomic Absorption Spectrophotometer
Perkin-Elmer model 603, Perkin-Elmer, Norwalk, CT.
b. Analytical balance

2. Reagents
a. Calcium standard 1000ug/ml, ordered from Fisher co.
b. Hydrochloric acid, ACS Reagent Grade, ordered from Fisher co.
c. Lanthanum oxide, ACS Reagent Grade, ordered from Fisher co.
d. Deionized-distilled water, made by Medical Preventive Lab, UMDNJ
e. Nitric acid (70% and 20%), ordered from GFS Chemicals, Columbus, OH
f. Perchloric acid (70%), ordered from GFS Chemicals, Columbus, OH

3. Glassware
a. Beaker

(24) 40m1

b. Eppendorf/repipet

(1) 12.5 ml reservoir

16

17

c. Graduated cylinder

(1) 25m1

d. Graduated cylinder

(1) 250m1

e. Volumetric flask

(24) 25m1

f. Volumetric flask

(7) 100m1

g. Volumetric flask

(2)

h. Volumetric flask

(1) 1000m1

i. Plastic tube

(48)

500m1

10m1

5.2 Solution Sample Acquisition and Preparation
This analysis was to monitor the calcium in the solution which were changed
every week in the in-vitro test. The range of the atomic absorption analysis data
from the spectrophotometer was 0 ~ 200 µg / dl. The reading data was
proportional to the calcium concentration in the above range. Therefore, the
solution sample need to be diluted to fall into the range if.their concentration were
higher than 200 µg / dl.
Since the calcium concentration was around 2.9 mM (i.e. 11600 µg/dl ),
the solution should be diluted at the ratio of 1:100.

5.3 Tissue Sample Acquistition and Preparation
Before being analyzed, tissue samples need to be digested with 3:1 nitric acid
(70%) / perchloric acid (70%), diluted with 1% lanthanum. The preparation and
analytical process takes 5 days. It was performed for 20 samples at the time. The
processes were as following:

1st day:
24 beakers were soaked with 20 % nitric acid overnight;
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2nd day:
a. The 20 % nitric acid was returned to the original acid bottle;
b. Each beaker was rinsed 5 times inside and outside thoroughly with distilled
water;
c. Each beaker was labelled;
d. Each beaker was dried in 90 °C oven overnight;
e. 24 flasks of 25 ml volume were soaked with 20 % nitric acid;
f. 48 plastic tubes were soaked with 20 % nitric acid;

3rd day:
a. The beakers were removed from the oven quickly, placed in desiccator for 10
minutes;
b. Each beaker were weighed and recorded;
c. Each beaker was returned to oven for another I hours;
d. Steps a and b were repeated, till constant weight; the weight was recorded as
WI;
e. The samples were placed into beakers;
f. 0.25g NBS was put in oven at 90 °C overnight;
g. All beakers were placed in oven at 90 °C overnight;
h. 20% nitric acid was returned from flasks and tubes to the original acid bottle.
Flasks and tubes were rinsed 5 times with distilled water, then air dried.

4th day:
a. Beakers were removed from the oven and placed in desiccator to be cooled to
room temperature (10 minutes);
b. Beakers were weighed and recorded;
c. Beakers were put in 90 °C oven for 1 hour;
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d. Repeat steps a and b, till the weight was constant. Then the weight was recorded
as W2, (the dry sample weight equal to W2 - WI);
e. Samples were digested at 150 —175 °C with 10 ml mixture acid solution of 3 : 1
nitric acid (70%) / perchloric acid (70%), till 0.5 ml liquor left in the beaker;
f. The liquor was washed 5 times with millipore water and quantitatively transfer
into 25 ml volumetric flask. Each time, the inside wall of beaker was washed as
completely as possible. Then the 25 ml volumetric flask was shaken to make the
solution sample uniform;
g. The contents of volumetric flask was transferred to a plastic test tube.

5th day:
The sample solution was diluted with 1% lanthanum to prevent interference from
silicon, aluminum, phosphate and sulfate, etc. Dilution ratio was chosen according
to the calcium concentration in the sample.

5.4 Standard Solution Preparation
1. Preparation of 5% Lanthanum solution
a. 29.32 grams of Lanthanum Oxide was transferred to a 500 ml volumetric flask;
b. 25 ml of distilled water was added and swirled;
c. 125 ml of concentrated hydrochloric acid was added slowly to the 50 ml
volumtric flask;
d. The solution was diluted with deionized-distilled water to 500 ml.

2. Preparation of calcium standards in 0.5 % Lanthanum solution
a. 100m1 of 5% lanthanum solution was diluted with 900m1 deionized-distilled
water to form a 0.5% lanthanum solution;
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b. 5.0 ml of calcium stock solution 1000 µg / ml was diluted to 100 ml in a
volumetric flask with deionized-distilled water. The solution is equivalent to 50
µg calcium / ml ;
c. The 50 jig Ca/ml solution was diluted with 0.5 % Lanthanum solution according
to the following ratios:

Ca Standard
g/10ml µ

Ca
50 µg/ml

0.5 %
Lanthanum

0

0

100

50

1

99

100

2

98

150

3

97

200

4

96

5.5 Analytical Procedures
1. Samples and standard solutions were prepared;
2. The power was turned on, appropriate lamp and burner head were installed;
3. The lamp current, read on the Lamp Current Meter (in the lamp compartment),
was set to the proper value with the lamp current control;
4. The slit and wavelength were set to proper values;
5. The SIGNAL control switch was set to CONC. (EM CHOP for flame emission
measurements) and the MODE control switch to HOLD ;
6. The BKGD CORR switch was set to AA-BG;
7. The gas controls was set up and the gas was ignited;
8. An integration time was selected by entering the desired value through the
numerical keyboard and the INT key was pressed (the initial integration interval
was set at 0.5 second when the instrument was turned on) ;
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9. A blank solution was aspirated and the A2 key was pressed to zero the digital
display;
10. Calibration of the instrument.
a. The desired value for Standard 1 was entered through the numerical keyboard
and the Si key was pressed;
b. Step a was repeat for S2 and S3;
c. Si was aspirated and the Si key was pressed;
d. Step c was repeated for S2 and S3. The standards must be aspirated in order of
increasing concentration, during the calibration of the instrument.
11. A sample solution was aspirated and the READ button was pressed. The
indicator dot above the READ button would be lit until measurement is
completed.
12. Analysis was performed at 428 nm using air-acetylene flame, and read on the
Perkin-Elmer model 603 atomic absorption spectrophotometer.

5.6 Calculation
5.6.1 Calcium Content in Solution Samples
If the dilution ratio was 20µl sample : 2000 µl 1 % lanthanum and the reading on
the atomic absorption spectrophotometer was 80 (µg / dl), then the calcium content
in the solution sample would be :
80 (µg/dl) x (2000 + 20 ) x10 (dl/l)
40 (g/mol) x 20 x 1000 (µg/mg)
2.02 mM. Ca

5.6.2 Calcium Content in Tissue Samples
If the dilution ratio was X, the reading on the atomic absorption spectrophotometer
was 80 (µg/dl), then the calcium content in the tissue sample would be:
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X x 80 (µg/dl) x 25 ml
100 (ml/d1) x (W2 - W1)
with the unit of µg Ca / mg dry tissue.

1

CHAPTER 6

RESULTS

6.1 In Vitro Calcification
6.1.1 Solution Sample Analysis Result in Vitro Studies
Table 6.1 summarizes the results of the solution analysis for calcium
concentration. Concentrations were expressed as mM. The average values were
expressed as mean ± stantard error of the mean (SEM). Statistical significance was
determined by two-tailed independent t-test.
The calcium concentration in the original fresh solution A was 2.88 mM.
There were two groups for each kind of pericardium in this test. For group 1, the
solutions were changed with fresh solution A and analyzed every week. The
results show that the average calcium concentration in the glutaraldehyde group is
significantly higher than that in the No-ReactTM group ( p < 0.01 ). For group 2, the
solution were not changed until the end of the test period (21 days). After 21 days,
the solutions were analyzed, the calcium concentration in the glutaraldehyde group
is also significantly higher than that in the No-ReactTM group ( p < 0.02 ). All these
illustrate that there is more calcium transfer to the glutaraldehyde treated
pericardium from solution A than to the No-React treated pericardium.

6.1.2 Tissue Sample Analysis Result in Vitro Test
. 21 days result
In this test, the calcium concentration of solution A was 2.88 mM. Table 6.2
summarises the result of the calcification of the two types of pericardium after 21
days incubation at 37°C. The average calcium content of the control (preincubation) conventional glutaraldehyde treated pericardial samples was 0.12
µg/mg dry tissue, the average calcium content of the control (pre-incubation) No-
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Table 6.1 In-Vitro Calcification Data: Calcium Content
in the Incubation Solution (mM)

Run #

lth week

2nd week

3rd week

Run #

3rd week

N1-1

2.70

2.80

2.80

N2-1

2.80

N1-2

2.88

2.88

2.75

N2-2

2.53

N1-3

2.88

2.78

2.85

N2-3

2.78

N1-4

2.80

2.88

2·88

N2-4

2.88

N1-5

2.88

2·83

2.88

N2-5

2.78

m ea n±SEM

2.83±0.04

2.83±0.02

2.83±0.03

G1-1

2.60

2.47

2.50

G2-1

2.63

G1-2

2·50

2·47

2.35

G2-2

2.50

G1-3

2.50

2.37

2.50

G2-3

2·42

G1-4

2.63

2·50

2.50

G2-4

2·53

G1-5

2·63

2.53

2·50

G2-5

2.40

2.57±0.03

2.47+0.03

2.47+0.03

mean +SEM

2.75±0.06

2.49+0.04
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ReactTM treated pericardial samples was 0.11 µg/mg dry tissue. After 21 days
incubation in solution A, the calcium content in group 1 of conventional
glutaraldehyde treated sample was 5.84 ± 0.67 µg/mg, that of No-React" samples
was 1.28 ± 0.17 µg/mg. The difference is statistically significant ( p < 0.001).
The calcium deposition on conventional glutaraldehyde treated sample is higher
than that on No-React" samples. The data in group 2 shows that the calcium
deposition in the group that the solutions were changed is much higher than that of
the group which the solutions were not changed, demonstrating the calcium
concentration of the solution as a factor which can affect the rate of calcium
deposition. Statistc shows the difference is very significant ( p < 0.001 ).
Figure 6.1 shows the test result.

2. 56 days result
In this test, calcium concentration of solution A is 1.8mM.
Table 6.3 summarises the result of calcification at different temperature.
Group 3 was incubated at 25 °C. The average calcium concentration in NoReact" group is 0.58 ± 0.04 µg/mg, while that in conventional glutaraldehyde
group is 0.94 ± 0.07 µg/mg. The difference between these two types of percardium
is very significant ( p < 0.01).
Group 4 was incubated at 37 °C. The average calcium concentration in NoReact group is 8.78 ± 1.02 µg/mg, while that in conventional glutaraldehyde
group is 14.58 ± 1.40 µg/mg. The difference between these two types of
percardium is significant ( p < 0.03 ).
The results show that the higher temperature the higher calcification rate.
The difference of calcification between two types of pericardium is more
significant at 37 °C than that at 25 °C. The temperature at which the incubation is
done plays a significant role in this calcification process in vitro test.
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Figure 6.2 shows the result of the in-vitro test after 56 days incubation as
well as other parameters.

6.1.3 Macroscopic Observation
In 21 days in-vitro test, from the 8th day of incubation, we began to watch the
pericardium surfaces. There were some white calcium spots attached on both
surfaces of the conventional glutaraldehyde treated pericardial samples. There
was almost no spot could be observed on the No-ReactTM treated pericardial
samples.
Table 6.4 is the record of the macroscopic observation. The spots on the
conventional glutaraldehyde group 1 (solution were changed every week) were
more than that oh group 2 ( solution were not changed during the test period).

6.2 Pronase Digestion Test
Table 6.5, 6.6 , 6.7 summarise the results of pronase digestion test of No-ReactTM,
glutaraldehyde , and fresh pericardial samples , respectively .
The results show that the weight loss of the above three types of pericardial
samples are 10.3 ± 0.6%, 14.8 ± 1.1%, and 62.4 ± 1.3% respectively. The
difference between any two of them is very significant ( p < 0.001).

6.3 In-vivo Test---Subcutaneously Implants in Rats
Table 6.8, 6.9, 6.10 summarise the results of calcification in pericardial samples
explanted at 15, 21 and 35 days, respectively. The calcium concentrations of the
pericardial samples were expressed as microgram calcium per milligram dry tissue
weight. Statistical significance was determined by two-tailed independent t-test.
The mean calcium content ± SEM of conventional glutaraldehyde treated
pericardium after 15, 21 and 35 days of subcutaneous implantation were 49.58 ±
9.60, 82.45 ± 10.40, and 134.32 ± 9.10 µg/mg, respectively. Comparatively, the
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mean calcium content of No-ReactTM treated pericardium was signigicantly lower
(p < 0.05) at each correstponding interval (19.58 ± 6.01, 32.27 ± 12.22, 21.43 ±
5.21µg/mg, respectively).
Figure 6.4, 6.5, 6.6 show the difference of calcificaiton in the two types of
pericardial samples and show the significant variance among each individual rats.
From these data, clearly the calcium content of the conventional glutaraldehyde
treated pericardium is significantly higher than that of No-ReactTM treated
pericardium. The calcium content increased significantly in conventional
glutaraldehyde treated pericardium as the time of implantation is increased, but
the No-ReactTM treated sample did not behave likewise.
Comparing these two types of pericardium, while for the conventional
glutaraldehyde treated pericardium the calcium content have increased with the
time of implantation, for the No-ReactTMtreated sample at 3 weeks, the calcium
content have increased slightly. For unclear reason, however, decreased at 5
weeks of implantation.

CHAPTER 7

DISCUSSION

In order to understand and interpret calcification both in-vitro and in-vivo, it is
necessary to know some of the properties of the valve materials and the current
hypotheses of normal and pathologic calcification processes.
Bioprosthetic valves --- bioprosthetic valves encompass all valves in which
the leaflet function is carried out by materials derived from animal sources. These
include homograft (allograft) valves derived from human cadavers, autografts
derived from the recipient's own body (the utilization of the pulmonary valve in
the aortic position) and heterografts derived from sources such as chemicallymodified bovine pericardium or whole porcine valves. In general, these valves are
mounted on some type of frame or scent for use. Therefore, they contain synthetic
materials such as metals and I or polymers in addition to animal tissue that has
usually been modified in some way.
The synthetic parts of these valves are more durable than the biologic parts.
Stent failure is reported as less than 0.001% per annum, compared with tissue
failure at a rate of 1% per annum. The latter is much higher than the failure rate
reported for mechanical valves and raises serious questions about the long-term
durability of these types of valves, with the exception of autograft valves which
performed best overall, but are not widely used. Overall, the quality of life with a
well-functioning biologic prosthesis is reported to be 'better than that with a
mechanical valve and degeneration is often a slowly progressing phenomenon that
can allow for planned reoperation.
Degenerated allograft valves have developed calcification, whereas
autografts are reported to have no evidence of calcification processes. Some
attempts have been made to construct valves out of human-source biomaterials
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such as fascia lata or dura mater, but with limited success as both these materials
tended to degenerate and calcify.
The first heterograft valves in use were chemically modified porcine aortic
valves. These valves have good commissural supports but the valve orifice is
increasingly restricted by a muscle shelf on the right coronary cusp, as valve size
decreases. Improved valve orifice and pressure characteristics were achieved by
using modified bovine pericardium to fabricate stent-mounted trileaflet valves.
The dialdehyde, glutaraldehyde, is commonly used to introduce a stable crosslinking network into the tissue, reducing its antigenicity and sterilising the tissue.
All heterograft valves calcify at varying rates after implantation and this
introduces a serious limitation on their useful life. This limitation is particularly
stringent in the case of valves implanted into children when the rate of
calcification of biologic prostheses is unacceptably high, resulting in early
malfunction of the valve.
Normal and pathologic calcification --- Normal calcification essentially
equates with bone formation. Bone is formed extracellularly in collagenous
matrices with deposition of hydroxyapatite, a crystalline form of calcium
phosphate containing 10 calcium atoms, six phosphate molecules and two
hydroxyl groups. Under normal conditions, the body's extracellular fluid is in a
metastable state i.e. spontaneous precipitation of calcium phosphate does not occur
although sufficient quantities of calcium and phosphate are present to allow
growth of crystal structures once precipitation is initiated. One hypothesis
proposes that the normal mineralization process is initiated by matrix vesicles:
small, membranous, extracellular particles which have been observed in
physiologic calcification as well as in some pathologic processes (14).
Three classes of abnormal calcification in the body have been identified:
heterotopic true.bone formation and two classes of soft tissue calcification, with
no distinct bone matrix structure, i.e. metastatic calcification associated with
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hypercalcaemia or hyperphosphataemia and dystrophic calcification associated
with normocalcaemia and normophosphataemia (15).
Heterotopic bone formation is often associated with the deposition of
cartilage and generation of new osteoblasts. The initial stimulus for this process is
unknown but may involve specific proteins e.g. bone morphogenic protein.
Alkaline phosphatase is often elevated. Heterotopic bone formation after hip
replacement surgery is more common in male than female patients. Studies of
cartilage calcification have observed deposition of the protein chondrocalcin,
identified as the c-propeptide of type II collagen, which is thought to bind to
proteoglycan aggregates and is known to bind calcium and hydroxyapatite (16).
Proteoglycan aggregates are not detected in non-calcifying cartilage. An ionexchange mechanism of cartilage calcification has also been suggested (17);
calcium is present in high concentration in cartilage, but, normally, is largely
bound to anionic groups of proteoglycans and hence inhibited from precipitating.
This hypothesis suggests a local increase in phosphate concentration to release
calcium from the proteoglycans, thus raising the calcium-phosphate product above
the threshold for hydroxyapatite precipitation.
Metastatic calcification occurs more frequently at sites where the local pH
is abnormally high, with a higher probability of the calcium-phosphate product
rising above the precipitation threshold. This commonly occurs in patients with
renal disease and can be prevented by reducing plasma phosphate with ingested
aluminum hydroxide. Ingestion of large amounts of phosphate has been shown to
result in metastatic calcification in animal experiments and may do the same in
humans (15).
Hypotheses of bioprosthetic heart valve calcification --- Calcification of
artificial heart valves is of the dystrophic type and may be intrinsic (directly
associated with the biomaterial) or extrinsic (superficial to the biomaterial and
associated with debris attaching to the surface of the material) to the material
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involved (18). The mechanism is obscure and there are several current hypotheses.
It has been reported that calcium is deposited earliest in connective tissue cells of
the valve material and later in collagen fibrils-calcification also occurred in
acellular collagen sponge implants. It is likely, therefore, that calcification is not
specific in terms of the gross picture of initiation sites, but may be specific to
molecular binding sites available on a variety of macromolecular structures.
Calcification may be mediated by extracellular vesicles. These could be
matrix vesicles as observed in physiologic mineralization, membranous cell
fragments produced as by-products of tissue damage or mitochondria of damaged
cells (14). Such vesicles have been proposed as a means of achieving locally high
concentrations of calcium and phosphate, with the initial site of crystal formation
being inside the vesicle. The presence of calcium-phosphate-acid phospholipid
complexes has been demonstrated in matrix vesicles and membrane fractions (19).
These complexes, in vitro, were capable of nucleating hydroxyapatite but, in vivo,
there is no evidence of crystalline calcium phosphate being stored in intact
vesicles. It is thought that magnesium present in vivo stabilises amorphous calcium
phosphate in the vesicles and that nucleation of hydroxyapatite does not occur
until the membrane is ruptured, releasing the magnesium and exposing the
complex to the extracellular fluid.
When tissue damage occurs, the normal homeostatic mechanisms for
removing intracellular calcium may break down resulting in a massive build-up of
calcium within the damaged cell or cell fragment by passive diffusion from the
extracellular fluid. The calcium-phosphate product is then exceeded and
spontaneous crystal precipitation occurs within the membrane. This hypothesis
could account for both intrinsic and extrinsic calcification observed in artificial
heart valves: extrinsic calcification would occur when dead or damaged cells or
cell fragments lodged on the surface of valve leaflets and then calcified, whereas
intrinsic calcification would occur to the damaged cells present in the leaflet tissue
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itself due to the pretreatments with chemicals such as glutaraldehyde, or because
of mechanical damage resulting from leaflet flexion. By this mechanism, it would
be obvious that calcification of valves made from artificial polymers e.g.
polyurethanes could only be of the extrinsic type.
In leaflet samples implanted subcutaneously in rats and enclosed in
Millipore filters, calcification still occurred, implying that host cellular factors, at
least, are not involved although damaged cells present in the leaflet material may
still be a factor. This work also implies that calcification is not related to host
immunologic processes, as does work with athymic mice in which implants
calcified as readily as in normal mice. In vitro experiments have shown that
collagen is capable of taking up calcium and phosphate.
The main sites of calcific deposition in porcine bioprostheses were shown
to be within the cuspal connective tissue and in small surface thrombi (20). The
initial form of deposition was amorphous calcium phosphate and the concept
proposed was that phosphate formed covalent bonds connecting inorganic and
organic components through the E-amino groups of lysine and hydroxylysine in
collagen. Many hydroxylysine groups are normally glycosylated and it was
suggested that proteoglycans and glycoproteins normally mask such binding sites
and that these are lost during glutaraldehyde processing thus unmasking calcium
phosphate binding sites in the tissue. Calcium phosphate uptake by collagen has
also been associated with proteolipid bound to collagen. Collagen plus proteolipid
calcified in a metastable calcium phosphate solution whereas collagen minus
proteolipid failed to calcify and proteolipid alone did calcify. The proteolipids
concerned were composed of hydrophobic protein with acidic phospholipid and
had high affinity for collagen. Neither the hydrophobic protein nor the acidic
phospholipid fraction was capable of initiating calcium phosphate crystallization
alone and, even in complex, some of the lipid components seemed to possess an
inhibitory function and may perform a regulatory function in vivo. Proteolipids, of
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course, are present in all membrane structures and may be relevant to the proposed
mechanism of nucleation of calcification by membranes and matrix vesicles.
Proteins, such as osteocalcin, which contain the amino acid gammacarboxyglutamic acid, have a strong affinity for calcium. The synthesis of such
proteins are dependent on vitamin K. They have been found in close association
with regions of extending mineralization, and quantities of these proteins in
implants have been found to increase proportionally with calcium (21). Warfarin,
however, as an inhibitor of vitamin K-dependent processes did not block
calcification, although osteocalcin found in implants was reduced (22). This
protein may act as a metabolic control of calcification by binding calcium and
hence making it unavailable for proliferation of hydroxyapatite. Another gammacarboxyglutamic acid-containing protein, atherocalcin, has been found in
atherosclerotic plaques and, unlike osteocalcin, had been observed to enhance
hydroxyapatite formation.
Studies of calcified human aortas have shown significant increases in the
cross-linked peptide, histidinoalanine, which occurs in an acidic protein probably
associated with collagen or elastin. The histidinoalanine was concentrated in the
mineralized regions of the aortic tissues. It is unknown whether this peptide is part
of the calcified elastin in the aortic tissue or is part of a discrete peptide present in
the tissue (23).
The concept of "neutral binding site/charge neutralization" has been
proposed to explain calcification of aortic elastin. This hypothesises that the
binding sites for calcium are the carbonyl oxygens of the peptide backbone. The
positively charged bound calcium would then sequester phosphate to maintain
charge neutrality, thus developing the potential for hydroxyapatite formation.
Support for this concept was obtained by chemically blocking purified elastin to
achieve neutrality and obtaining significant binding of calcium: exposure of
blocked elastin to calcium and phosphate solutions resulted in calcification of the
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elastin distributed throughout its bulk (24). It is also suggested that , normally in
vivo, elastin is protected from calcification by the close association of
proteoglycans and glycoproteins. Model peptides were shown to bind calcium via
the carbonyl oxygens of their peptide backbones. Collagen has the potential to
react similarly.
It has been suggested that calcification results from the removal of specific
inhibitors. This mechanism implies that, under normal physiologic conditions,
calcification is regulated by the presence of inhibitors and that mineralization only
occurs locally where these inhibitions have been removed. Proteoglycans have
previously been noted in this context. Nucleotide di- and tri-phosphates, low
molecular weight metabolites with two ester phosphates, and pyrophosphate
inhibit the transformation of amorphous calcium phosphate into hydroxyapatite
(25). Alkaline phosphatase reverses this inhibition and has been suggested as a
possible agent for promotion of mineralization. The action of alkaline phosphatase
is of particular interest in view of the accelerated calcification of artificial heart
valves implanted in children and the elevated amounts of the 'bone' isoenzyme of
alkaline phosphatase found in this group compared with the adult population (26).
Early experimental work on synthetic elastomeric heart valves indicates that
calcification may also be a problem for these materials. A polytetrafluoroethylene
valve developed progressive calcification associated with an expanded form of the
material and infiltration of the material by host cells (27). Polyurethane valves
implanted in calves calcified primarily at the material surfaces. Similar valves
calcified in sheep but no descriptive detail was reported (28). The problem has
also been observed in polyurethane-coated blood pumps, such as ventricular assist
devices and artificial hearts, in which the calcification has been associated with
stresses and defects in the material. The association of calcification in such valves
with the material itself (intrinsic calcification) or with host factors attaching to the
material (extrinsic calcification) is not yet clear· If the synthetic elastomer is
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directly involved, then the calcification mechanisms suggested so far seem
inadequate. The features common to all these valve types include flexibility,
permeability and the ability to adsorb I absorb certain blood components.
A physico-chemical hypothesis of calcification has been proposed by Bruck
(29), and it relates to the penetration and absorption of blood components by
flexing, deforming elastomers. Relevant factors in this process include
thermodynamic solubility parameters, domain structures, defects and porosity. All
these factors are functions of chemical composition, molecular weight and its
distribution, branching and cross-linking, the presence of amorphous and
crystalline domain structures, chain stacking and kinking. Absorption of blood
substances into the elastomer is closely related to the thermodynamic solubility
parameters of the biomaterial and the absorbed substance. By this principle,
absorption of water, native proteins and phospholipids by either valve type is
unlikely. Glutaraldehyde-treated tissue valves could absorb lipid-soluble vitamins
as could polyurethanes. The polyurethane soft segments, however, would also
absorb triglycerides, cholesterol and esters. Bruck concludes that these materials
will always absorb some blood components and that this process, over time, will
lead to biomaterial degradation. The direct relationship to calcification is not clear,
but it has been suggested that lipid components absorbed in this way by polyether
soft segments of polyurethanes initiate calcification in vivo by complexation.
The effect of polyurethane porosity has been studied. As porosity of the
material increased, the degree of tissue ingrowth increased, but there was no
relationship between porosity and calcification, at least in materials implanted
infra-muscularly in rats up to 12 weeks. Specimens seeded with calcium, however,
showed extensive calcification with limited tissue ingrowth (30).
Several groups postulate a close connection between the mechanical stress
applied to the xenograft valve and the calcification process. It is unclear whether
damage caused by the mechanical stress initiates calcification or calcification
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caused increased stress resulting in membrane rupture. It has been shown that
calcification occurs in regions of highest stress-strain (31).
This relationship has been more closely investigated by Deck et al. (32) and
Thubrikar et al. (33), who postulated that collagen breakdown is initiated by
excessive wear caused by mechanical stress. These authors implanted porcine or
pericardial valves into calves with or without radio-opaque markers tagging the
leaflets. Calcification occurred at regions of highest stress for both types of valve,
but there appeared to be a difference in mechanism. The porcine valves developed
visible calcification later than the pericardial valves and appeared to be subject to a
mode of deformation resembling pure bending i. e. with the formation of internal
voids within the leaflet tissue in which the calcium was initially deposited.
Pericardial valves, in contrast, showed early visible calcification and a deformation
mode of internal shearing, creating clefts between layers of collagen with
calcification of the collagen along the planes of shear. Suggested mechanisms for
the calcification include exposure of calcium-binding sites of collagen, or the
appearance of collagen breakdown products capable of initiating calcification.
Simple surface damage to the leaflets as caused by the radio-opaque tags did not
appear to enhance calcification.
Work with valved ventricular assist devices implanted in calves found
microscopic calcification within the pseudoneointimal layer which was closely
associated with the flexing region of the pump. It was proposed that intrinsic
calcification was of mechanical origin and that high cyclic strains disrupted the
pseudoneointimal structure, thus initiating calcification in some way. They tested
several tissue valves, finding that bovine pericardial valves gave the highest
incidence of calcification compared with porcine or human dura mater valves.
The relationship between mechanical stress and calcification is supported
by reports that implants in the right side of the heart are less subject to
calcification than those in the left side (34). The stress levels on closed valves in
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the mitral position are greater than in the aortic position, both of which are greater
than those in the tricuspid position. One study of bioprosthetic valves explanted
from juvenile sheep contradicts theses findings, with valves explanted from the
tricuspid position being more heavily calcified than valves from the mitral
position (35).
An accelerated rate of mechanical damage, caused by increased stresses due
to relatively small valve orifices combined with higher resting heart rates in
children compared with adults may contribute to the accelerated calcification of
bioprosthetic valves seen in this group.
Finite element analysis has been used to show a similar strong correlation
between stress-strain distribution and calcification in polyurethane diaphragms of
blood pumps, with surface defects forming in the flexing regions. It has been
further suggested that substantial heat is generated by flexing polyurethane
membranes which would accelerate any chemical process, e.g. calcification,
occurring in the vicinity. It is also possible that disruption of the surface structure
of the polymer during flexion would expose calcium binding sites and thus
enhance calcification. This is important particularly in view of the propensity of
polyurethane materials to creep over time, resulting in thinning of the polymer
structure and ,probably, greater exposure of segment components normally buried
within the polymer which might have increased affinity for calcium phosphate.
This process is likely to be enhanced in flexing structures.
There are many hypotheses relating to the process of biomaterial
calcification. Many of these would seem to be more in the nature of promoting or
inhibiting factors affecting the process, and the primary event has not yet been
clearly defined. It is not clear whether calcification is intrinsic to the biomaterial
itself or due to extrinsic factors, e.g. calcification of cell debris attached to
biomaterial surfaces. In the latter case, procedures to improve biocompatibility,
particularly with polyurethane materials, might prove beneficial.
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It would seem logical to expect a similar mechanism of calcification to
operate, whatever the biomaterial involved and if, of course, that material calcifies.
Thus a likely candidate for a general calcification mechanism is cation chelation
by groups present in the material, containing lone pairs of electrons susceptible to
interactions with electron-deficient species. Such groups are available in both
biologic and synthetic elastomeric materials: the carbonyl oxygens of the backbone
of collagen and the polyether/polyester oxygens of the soft segments of
polyurethanes. Carbonyl oxygens of the urethane and urea linkages of
polyurethanes potentially could also be involved. Phosphate would be carried
along in the process as the accompanying anion to maintain charge neutrality.
This mechanism could explain both intrinsic and extrinsic calcification, as
cell debris causing extrinsic calcification would have similar binding sites to
initiate calcification. By this mechanism, other factors would simply shift the
equilibrium of the calcium-binding process in one direction or the other; if the
shift were towards calcium binding , then the degree to which that occurred might
influence mineralization by increasing the local calcium-phosphate product above
the level needed for precipitation. Once hydroxyapatite was formed the reaction
would be irreversible as the product is insoluble.
A further implication of this hypothesis is that calcification would not be
dependent on biologic processes but should also occur in vitro under relatively
simple reaction conditions. If this proved to be the case, it should be possible to
obtain a clearer definition of the primary process involved in calcification. The
development of controllable in vitro calcification systems should enable the
advance of understanding of calcification and its control.
The results presented here indicate that much greater calcification is
produced by in vivo than in vitro methods, although significant calcification is
produced in vitro. Calcification in vivo occurs relatively rapidly and thus it is
difficult to produce controlled low degrees of calcification for investigation of the
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early stages of the process. Selection of specific degrees of calcification is much
simpler in the in vitro systems in which the specimens may be observed
continually.
Static tests in vitro did produce calcification, but the degree of calcification
produced under these test conditions was extremely low, although significantly
greater than uncalcified control material. The testing time could extended and the
test solutions replenished at intervals, thus maintaining the supply of calcium and
phosphate to the test material over long periods of time and increasing the degree
of calcification achievable by this system. The prime disadvantage of such static
systems is their inability to test the biomaterial in similar configuration and stress
conditions under which it would be expected to function as a heart valve.
Calcification has been studied both in vivo and in vitro. The in vitro tests
have demonstrated that specific blood factors are not required for calcification to
take place, although theses may influence the rate of reaction. The hypothesis of
Levy et al (35). regarding the role of localized tissue phosphate as a focus of initial
calcification may be supported by the erratic early uptake of phosphate from the
calcifying solution in this study, which does not begin to parallel calcium uptake
until the calcification process is well established.
The association of calcification with surface trauma may be a result of
exposure of free binding sites for calcium within the pericardial tissue, previously
protected by the intact pericardial surface. It is not known whether this is a feature
of damage to collagen fibres perse or related to a difference in the quality of
chemical modification of the pericardium, by glutaraldehyde, between the surface
and sub-surface regions of the tissue. It is worth, however, emphasizing the need
for careful handling of bioprostheses prior to and during implantation, to minimize
the likelihood of compromising the lifetime of the valve.
The No-ReactTM anticalcification treatment as well as the conventional
glutaraldehyde process are two different modifications of the pericardial tissue. In
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this test series, both in vitro and vivo test show that glutaraldehyde treated
pericardium sample calcified to a much greater extent than No-ReactTM treated
pericardium sample. This also illustrates the ability of the No-ReactTM treatment to
significantly delay the degenerative mineralization of bovine pericardial tissue.
Therefore, the way of modification plays an important role in the calcification
process.
The pronase digestion test shows that the No-ReactTM samples have less
weight loss after digestion, and glutaraldehyde samples are richer in type I
collagen. It has been suggested that the inflammatory response is due to
chemotactic potential of collagen peptides generated from the collagenase
digestion. Furthermore, our experiments show that although initiation of tissue
mineralization does not require host mediated response, the in-vivo milieu has
potentially an important role in accelerating the calcification process. This
phenomenon is further illustrated by the intense inflammatory reaction and the
resulting tissue disruption noted in our morphological examinations of
glutaraldehyde treated pericardium, and the remarkable absence of such
destructive features in No-ReactTM treated tissue. Probably, this is one of the
reasons that No-ReachTM treated samples are less calcified than that treated by
glutaraldehyde. Further experiments needed to be performed to investigate the
mechanism of the calcification and their difference between the two kind
modifications.
Materials which calcify rapidly in these systems are unlikely to do better in
humans. Material which show promise in these test systems may be selected for
more intensive investigation in-vivo to decide whether or not their promise will
extend to the ultimate, human implanted valve.

CHAPTER 8

SUMMARY

In this study, we compared calcification of bioprocess of No-ReactTM and
conventional glutaraldehyde treated pericardium by both in-vivo and in-vitro
methods. The results presented here indicate that much greater calcification is
produced by in-vivo method than by in-vitro method. Static test in-vitro did
produce calcification maintaining the supply of calcium and phosphate to the test
material increase the calcification. Temperature is one of the factors affecting
calcification. The calcification of glutaraldehyde treated pericardium is more
severe than No-ReadTM treated pericardium both in-vivo and in-vitro test. The invivo test also shows that there is a substantial variance in the rate of calcification
of tissues implanted in apparently the same group of animals (rats).
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APPENDIX A

Appendix A contains the tables of the experimental results in Chapter 6.
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Table 6.2 In-Vitro Calcification Data: 21 Days Incubation
Results (Tissue Samples)
Run

Solution

tissue dry

initial Ca

final Ca

Ca increase

#

change

weight(mg)

(ug / mg)

(ug/mg)

percentage

G1-1

yes

80.9

0.12

7.48

6031%

G1-2

yes

83·4

0.12

6.66

5372%

G1-3

yes

87.2

0.12

4.29

3459%

G1-4

yes

76.1

0.12

4.55

3672%

G1-5

yes

101.5

0.12

6·20

5004%

5.84±0.67

4707%

mean±SEM
G2-1

no

72.5

0·12

4.82

3885%

G2-2

no

101.5

0.12

1.65

1333%

G2-3

no

102.8

0·12

2.94

2373%

G2-4

no

69.1

0.12

4.38

3530%

G2-5

no

87.2

0·12

3.94

3179%

4.02±0.34

2860%

mean±SEM
N1-1

yes

58.1

0.11

1.47

1287%

N1-2

yes

94·1

0·11

0.94

820%

N1-3

yes

77.5

0·11

1·85

1619%

N1-4

yes

77.1

0.11

1.07

939%

N1-5

yes

66·4

0.11

1.08

945%

1.28±0.17

1122%

mean±SEM
N2-1

no

61.6

0.11

1·03

901%

N2-2

no

69·2

0·11

1.19

1046%

N2-3

no

77.8

0.11

0.92

806%

N2-4

no

73.6

0·11

1·05

918%

N2-5

no

58·3

0·11

1.13

993%

1.06±0.05

933%

mean±SEM
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Table 6.3 In-Vitro Calcification Data: 56 Days Incubation
Results (Tissue Samples)

Run

Temperature

Ca (µg/mg)

Ca (ug/mg)

( C)

No-React group

glutaraldehyde group

3-1

25

0·44

0.69

3-2

25

0.67

0·92

3-3

25

0.54

0.98

3-4

25

0·66

1·14

3-5

25

0.58

0.96

0.58±0.04

0.94+0.07

#

mean±SEM

4-1

37

7.54

18·78

4-2

37

5.78

11.48

4-3

37

9.57

11.71

4-4

37

9.12

16.45

4-5

37

11.87

14.49

8.78±1.02

14.58±1.40

mean±SEM
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Table 6.4 In-Vitro Calcification Data: Calcium Spots
on the Pericardium Samples

day #

1

8

9

12

13

14

15

16

19

21

G1-1

0

5

6

8

9

10

11

11

11

12

G1-2

0

2

2

5

5

5

6

6

7

8

G1-3

0

5

7

7

8

8

9

9

9

9

G1-4

0

3

3

4

4

4

5

5

6

6

G1-5

0

2

2

3

4

4

4

4

4

4

G2-1

0

7

8

8

8

8

8

8

8

9

G2-2

0

0

0

0

2

2

2

2

3

3

G2-3

0

0

1

2

2

2

2

2

3

4

G2-4

0

1

2

3

3

3

3

3

3

3

G2-5

0

6

6

6

6

6

6

6

6

6

N1-1

0

0

0

0

0

0

0

0

0

0

N1-2

0

0

0

0

0

0

0

0

0

0

N1-3

0

0

0

0

0

0

0

0

0

0

N1-4

0

0

0

0

0

0

0

0

0

1

N1-5

0

0

0

0

0

0

0

0

0

0

N2-1

0

0

0

0

0

0

0

0

0

0

N2-2

0

0

0

0

0

0

0

0

0

0

N2-3

0

0

0

0

0

0

0

0

0

0

N2-4

0

0

0

0

0

0

0

0

0

0

N2-5

0

0

0

0

0

0

0

0

0

0

G1-1 to G2-5 -- Conventional glutaraldehyde treated pericardium
N1-1 to N2-5 -- No-React treated pericardium

Table 6.5

Pronase Digestion Data: No-ReactTM Treated Sample

Run

initial

wet

dry

Ratio of

initial

final

after digest

Ratio of

Weight

No.

wet big

small

small

small dry/wet

dry big

dry big

wet big

fin/ini dry big

loss

1

107·8

38.1

13·2

0·35

37.3

32.8

95.7

0.88

12.2%

2

99·4

34.5

12.5

0·36

36.0

31.5

93.6

0.87

12.5%

3

128.5

35.8

12.8

0.36

45.9

41.5

111·3

0.90

9.7%

4

154·6

77.4

25.6

0·33

51.1

47·4

147.8

0.93

7.3%

5

125.4

42·5

15.5

0·36

45.7

41.8

124.8

0·91

8.6%

6

126.9

39·2

13·7

0.35

44.4

40.1

115.3

0.90

9.6%

7

128.0

53·1

17.9

0·34

43.1

38.7

130.0

0.90

10.3%

8

128.7

43·6

16·6

0.38

49.0

43·3

129.1

0.88

11.6%

9

154·1

78.4

29.3

0.37

57.6

52.5

169.7

0.91

8.8%

10

119·8

50.3

16.7

0.33

39·8

34.9

114.2

0.88

12.3%

mean±SEM

10.3+0.6%

Table 6.6 Pronase Digestion Data: Glutaraldehyde Treated Samples

Run

initial

wet

dry

Ratio of

No.

wet big

small

small

small dry/wet

1

157.8

34·8

9.2

0.26

41·7

2

196.0

76.3

20.8

0.27

3

104.7

46.3

13·1

4

142.0

58.1

5

134.6

6

initial

final

after digest

Ratio of

Weight

wet big

fin/ini dry big

loss

37.3

129.0

0.89

10.6%

53·4

46

160.2

0.86

13.9%

0.28

29.6

27

94.6

0.91

8.9%

16·2

0.28

39·6

32.3

118.8

0.82

18.4%

46.6

13·5

0.29

39.0

31.1

120.1

0.80

20.2%

210.2

67.4

18.7

0.28

58.3

50.1

180.2

0.86

14.1%

7

98.2

40.7

12.6

0·31

30.4

25.8

94.6

0.85

15.1%

8

178.8

51.7

15.0

0·29

51.9

44.7

171.8

0.86

13.8%

9

143.5

49.6

14.3

0.29

41.4

34.8

112.5

0.84

15.9%

10

175.2

75.3

22.1

0.29

51.4

42·7

162.6

0.83

17.0%

mean±SEM

dry big dry big

14.8±1.1%

Table 6.7 Pronase Digestion Data: Fresh Pericardial Samples
Ratio of

initial

Run

initial

wet

dry

No

wet big

small

small

1

210.1

111·7

33.9

0.30

63.8

2

179·2

67.3

21.9

0.33

3

137.2

101·2

30·7

4

117.2

49.5

5

180.3

6

final

after digest

Ratio of

Weight

wet big

fin/ini dry big

loss

27.9

76.0

0·44

56.2%

58.3

20.1

40.7

0.34

65.5%

0·30

41·6

14.6

42.8

0.35

64.9%

17

0.34

40.3

15.1

40·8

0.38

62.5%

78.7

24.7

0.31

56·6

21.9

65·1

0.39

61.3°A)

309

101.6

32.2

0·32

97.9

42.7

136.0

0·44

56.4%

7

122.3

55.2

19·9

0·36

44.1

15.2

37·0

0.34

65.5%

8

315

144.7

44

0·30

95.8

38.9

191.3

0.41

59.4%

9

92.7

36.7

13.9

0.38

35.1

12.4

38·9

0.35

64.7%

10

79

41

13.6

0.33

26.2

8.5

20.9

0·32

67.6%

mean±SEM

small dry/wet dry big dry big

62.4±1.3%
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Table 6.8 In-Vivo Calcification Data: Comparison of Calcium
Content between No-React and Glutaraldehyde
Treated Tissue Samples (15 Days)

specimen

initial Ca

tissue

final Ca

#

(ug/mg)

dry weight(mg)

(ug/mg)

N1

0.11

39.7

18.63

N2

0.11

33.7

7.63

N3

0.11

42.6

34.62

N4

0·11

40.5

1.46

N5

0.11

49.7

35.56

19.58±6.01

mean±SEM

GI

0.12

43.6

87.13

G2

0.12

47.8

46·91

G3

0·12

49.6

40·31

G4

0.12

42·6

33·43

G5

0.12

29·7

40·13

mean±SEM

49.58±9.60
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Table 6.9 In-Vivo Calcification Data: Comparison of Calcium
Content between No-React and Glutaraldehyde
Treated Tissue Samples (21 Days)

specimen

initial Ca

tissue

final Ca

#

(ug/mg)

dry weight(mg)

(ug/mg)

0.11

49.6

60.07

N2

0.11

43·4

17.45

N3

0·11

42.4

44.66

N4

0.11

54.9

6.90

N1

32.27±12.22

mean±SEM

G1

0·12

34.2

64·97

G2

0.12

43.1

64.01

G3

0.12

42.1

101·96

G4

0.12

47·1

98.85

82.45±10.40
mean±SEM
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Table 6.10 Comparison of Calcification In-Vivo Test between No-React
and Glutaraldehyde Treated Tissue Samples (35 Days)
specimen

initial Ca

tissue

final. Ca

#

(ug/mg)

dry weight(mg)

(ug/mg)

N1

0.11

34·5

14.6

N2

0.11

39.7

29.1

N3

0.11

53.4

32.0

N4

0.11

32.2

14·0

N5

0.11

60.7

7.5

N6

0.11

50.8

8·9

N7

0.11

37.9

43.8
21.43±5.21

mean±SEM
G1

0.12

35·7

140.8

G2

0·12

68·3

125.1

G3

0.12

85·9

169.6

G4

0.12

47.4

91·2

G5

0.12

54·4

135·8

G6

0.12

69.0

128·9

G7

0.12

52·3

148·9

mean±SEM

134.32±9.10

APPENDIX B

Appendix B contains the figures of the experimental results in Chapter 6.

Figure 6.1 21 Days In-Vitro Tests (Pericardial Samples)

Figure 6.2 Comparison of Calcification Rate between No-React and Glutaraldehyde Treated
Tissue Samples (56 days)

Figure 6.3 Calcium Spots on Pericardium Sample

Figure 6.4 Comparison of Calcification Rate In-Vivo Tests (15 days)

Figure 6.5 Comparison of Calcification Rate In-Vivo Tests (21 days)

Figure 6.6 Comparison of Calcification Rate In-Vivo Tests (35 days)
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